A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Element Drives Better Biocompatibility In the Medical Sector As Part of IMPULSO Project

Element Materials Technology (Element), a leading global Testing, Inspection and Certification (TIC) company, has concluded a 10-month investigation into the metal additive manufacturing (3D printing) of patient-specific spinal implants. The work has been undertaken as part of the IMPULSO Project, with results indicating a bright future for patient safety and greater innovation between the aerospace and medical sectors.

The IMPULSO Project is an initiative funded by the Spanish Government’s Ministry of Industry, Trade and Tourism, alongside the European Union (EU), to stimulate collaboration and technological development amongst Innovative Business Clusters (AEI). As part of the Andalucia Aerospace Cluster (1), Element contributed to the discovery of how metal 3D printing, a well-established method in the aerospace sector, could be applied to the medical world to increase access to bespoke implants for patients and implant turnaround times for practitioners.

The consortium sought to create a simple and efficient methodology for implants to be incorporated into production and manufacturing. To achieve this, Element’s experts undertook a rigorous technical study to measure the implant prototypes against existing tests needed for medical device certification. This included mechanical properties testing, manufacturing process quality control and an assessment of different bio-active coatings and trabecular structures, both of which, in this case, accelerate the osseointegration process and stimulate geometry of the spine’s inner structure.

Element Seville initially worked with doctors at the Hospital Clínico Universitario de Valladolid to understand what type of implant was most needed and would benefit from the highly detailed capabilities of 3D printing. A grade 5 titanium lumbar implant (Ti6Al4v) was the result, featuring a lattice design and porous structure to create a product with exceptional mechanical properties and better biocompatibility with the human body.

By evaluating key parameters such as the adherence strength and thickness repeatability for bio-active coatings, or cavity size distribution of trabecular structures, Element can now recommend manufacturing techniques that will contribute to a better quality of life for patients, decreasing recovery times and improving implant durability.

Miguel Ángel Jiménez, R&D Manager at Element Seville, said: “We are proud to have been a part of this project which will improve the quality of life for patients in the future and make tomorrow safer than today.

“It has demonstrated how different sectors and areas of expertise can learn from each other and reinforces that knowledge sharing is key to innovation. In particular, we found great value in collaborating with our colleagues at Element Cincinnati and in our Digital Engineering business unit to harness complementary capabilities.”

Mélanie Durth, R&D Manager at Andalucía Aerospace Cluster, added: “This project, developed between several Andalucian companies within the Cluster, allows us to evaluate the aerospace technologies available in the region and to further adapt them for other specialist industrial sectors. Moreover, it is a real opportunity for our associated companies to work together and create new synergies between bellwether companies and SMEs.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy